Id-2在结直肠癌组织中的表达及临床意义

Clinical significance of inhibitor of differentiation 2 expression in colorectal cancer

目的探讨分化抑制因子2(Id-2)在人结直肠癌组织中的表达及其与患者临床病理参数和预后的关系。方法选择2013年1月至2015年6月在我院手术治疗的结直肠癌患者56例为研究对象。采用免疫组织化学法检测所有患者肠癌组织和其中26例患者癌旁正常肠上皮组织中Id-2的表达水平,比较阳性与阴性表达者间的年龄、性别、病理分级、临床分期、淋巴结转移和预后的差异。结果免疫组织化学染色显示,Id-2主要表达于胞浆,其在肠癌组织和癌旁组织中的阳性表达率分别为64.3%(36/56)和34.6%(9/26),癌组织阳性表达率明显高于癌旁组织,差异有统计学意义(P<0.05);临床病理特征分析显示,在结直肠癌中,Id-2阳性表达与患者TNM分期(P<0.05)、病理分级(P<0.05)和淋巴结转移(P<0.05)有关,阳性患者Ⅲ~Ⅳ、低分化及有淋巴结转移者比例明显高于阴性患者,差异均有统计学意义(P<0.05);Id-2阳性患者的中位无疾病进展生存时间为24.7个月,阴性患者为38.5个月,两组比较差异有统计学意义(HR=2.23,95%CI:1.02~4.87,P<0.05)。结论 Id-2蛋白可能与结直肠癌的发生发展有关,且阳性患者预后较差。

Objective To evaluate the association between inhibitor of differentiation 2(Id2) expression and clinical characteristic in patients with colorectal cancer. Methods Fifty-six patients with colorectal cancer, who underwent surgery in our hospital from Jan 2013 to Jun 2015, were enrolled in this study. The Id2 expression of 56 cases of cancer tissue and 26 cases of normal tissue were tested by immunohistochemistry. The associations between inhibitor of differentiation 2 expression and age, gender, pathology grading lymph node metastasis and prognosis in colorectal patients were analyzed. Results The immunohistochemistry showed that Id2 was general expressed in the cytolymph. The positive expression rate of Id2 in cancer tissue [64.3%(36/56)] was significantly higher than that in normal tissue[34.6%(9/26)], P<0.05. Clinical pathological features analysis showed a significant association between Id2 positive expression and clinical stage(P<0.05), pathology grading(P<0.05), lymph node metastasis(P<0.05). The proportion of poor differentiation, stage Ⅲ~Ⅳ, lymph node metastasis in Id2 positive expression patients was significantly higher than those in negative expression patients(P<0.05). The median survival time of disease progression in Id2 positive patients(24.7 months) was significantly lower than that in Id2 negative patients(38.5 months), P<0.05. Conclusion Id2 may play an important role in the development of colorectal cancer, which could be a biomarker for prognosis.